Search Results - technology+classifications+%3e+therapeutic+modalities+%3e+small+molecules

151 Results

Sort By:

Prodrug for Immunological and Oncological Therapy

Unmet NeedApproximately 1.24 million hematological cancer cases occur each year, accounting for approximately 6% of all cancer cases (Bristol Myers Squibb). Currently, standard treatment strategies include chemotherapy, radiation therapy, and stem cell transplants. However, there exist several major drawbacks for each method. Stem cell transplants can...

Published: 5/2/2024 | Inventor(s): Barbara Slusher, Rana Rais, Franco D'alessio, Pavel Majer, Marcela Krecmerova, Srinivasan Yegnasubramanian

Keywords(s): Blood Cancer, Cancers, Disease Indication, Inflammatory Disorders, Respiratory Infections, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutic Substance Synthesis Method, Therapeutics, Transplants

Category(s): Clinical and Disease Specializations > Oncology > Hematologic Malignancies, Clinical and Disease Specializations > Transplantation, Technology Classifications > Therapeutic Modalities > Small Molecules

Diagnostic and therapeutic target for primary dysautonomia

Value Proposition:· Diagnostic target for broad primary dysautonomia screening.· Broadly applicable therapeutic target for symptom relief in primary and secondary dysautonomia patients.Technology DescriptionResearchers at Johns Hopkins have identified a potential diagnostic and therapeutic target for patients with primary dysautonomia....

Published: 5/3/2024 | Inventor(s): Malcolm Brock, Frank Bosmans

Keywords(s):

Category(s): Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities > Small Molecules

Alkylsulfenyl Thiocarbonates as Precursors to Hydropersulfides

Unmet Need:According to a survey by the CDC, nearly 50% of Americans age 20 and up have some form of cardiovascular disease (see AHA). The management of cardiovascular diseases depends on the specific indication, and standard therapies include one or multiple of the following types of medications: blood thinners, ACE inhibitors, beta-blockers, calcium...

Published: 5/3/2024 | Inventor(s): John Toscano, Vinayak Khodade, Sahil Aggarwal, Nazareno Paolocci, Blaze Pharoah, Gizem Keceli, Kelsey Zhang

Keywords(s):

Treatment of Irritable Bowel Syndrome with Molybdenum

Unmet NeedIrritable Bowel Syndrome is a chronic and incurable gastrointestinal disorder that affects 3-20% of Americans depending on certain sociocultural and comorbid factors. A poorly understood condition, current treatments consist of antispasmodics, antidiarrheals, and dietary restrictions. Unable to alleviate all its symptoms, researchers are in...

Published: 5/2/2024 | Inventor(s): Pankaj Pasricha, Lian Sheng Liu, Qian Li, Alfred Spormann

Keywords(s): Disease Indication, Gastrointestinal Disorders, Inflammatory Bowel Disease (IBD), Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Gastroenterology > Irritable Bowel Disease

Inhibition of rip kinases for treating neurodegenerative disorders

Unmet NeedNeurodegenerative disorders are a heterogeneous group that includes Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), dementia, and Huntington’s disease. These disorders result from progressive degeneration of the structure, function, and network of neurons in the central nervous...

Published: 5/2/2024 | Inventor(s): Seulki Lee, Han Seok Ko, Ted Dawson, Martin Pomper, Donghoon Kim, Yumin Oh, Seung-Hwan Kwon, Yong Joo Park

Keywords(s): Alzheimer's Disease, Antagonists/Inhibitors, CNS and Neurological Disorders, Disease Indication, Neurodegenerative Diseases, Parkinson's Disease, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Neurology > Neurodegeneration, Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Parkinson’s Disease

GCPII Inhibition for the Treatment of Sarcopenia and Aging

Unmet Need:Sarcopenia is the progressive loss of muscle mass and function, and is a natural part of the aging process. Age-related muscle loss and weakness can contribute to frailty and increase the likelihood of falls and fractures in older adults. Recent reports found that 5-13% of persons over the age of 65 years and >50% of people 80 years and...

Published: 5/3/2024 | Inventor(s): Barbara Slusher, Carolyn Tallon

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Geriatrics

DOPA and Caffeic Acid Analogs as Novel GCPII Inhibitors

Unmet NeedGlutamate is the primary excitatory neurotransmitter in the human brain [1]. Excessive glutamate signaling can disrupt calcium homeostasis, leading to mitochondrial dysfunction, the overproduction of reactive oxygen species, and neuron loss via necrotic or apoptotic pathways [2]. This phenomenon, known as excitotoxicity, contributes to disease...

Published: 5/3/2024 | Inventor(s): Barbara Slusher, Rana Rais, Takashi Tsukamoto

Keywords(s):

Category(s): Clinical and Disease Specializations > Neurology, Technology Classifications, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Small Molecules

Preventing Acute Kidney Injury Using JHU083

Unmet Need: It is estimated that 13.3 million people worldwide are affected by acute kidney injury (AKI) (see Bjornstad et. al). AKI is an especially prevalent condition in kidney transplant recipients, with one study showing that 35% of recipients had at least one episode of AKI (see Palmisiano et. al). These injury events lead to worsening kidney...

Published: 5/3/2024 | Inventor(s): Hamid Rabb, Barbara Slusher, Jonathan Powell, Kyungho Lee, Elizabeth Thompson, Sanjeev Noel, Sepideh Gharaie

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Nephrology

Methods to Treat Neurodegenerative Diseases

Unmet NeedAn estimated 930K people in the US are living with a neurodegenerative disease (Alzheimer’s and Parkinson’s are most common). However, current standard of care treatments mostly addresses symptoms of these diseases. To date no disease modifying or neuroprotective treatments are approved for Parkinson, and only 1 recently has been for Alzheimer’s...

Published: 5/3/2024 | Inventor(s): Rana Rais, Barbara Slusher, Arindom Pal

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Multiple Sclerosis, Clinical and Disease Specializations > Neurology > Amyotrophic Lateral Sclerosis, Clinical and Disease Specializations > Neurology > HIV-Associated Neurocognitive Disorders

Novel Therapeutic Drug for Multiple Sclerosis

INVENTION NOVELTY This molecule, through its action on a unique target that is different from current therapeutic treatments for MS, has both immunosuppressive and neuromodulatory properties that will better prevent the progression of MS and repair the neuronal damage caused by the immune cells in MS. Currently, there are no MS drugs in the market...

Published: 5/2/2024 | Inventor(s): Paul Kim, Michael Kornberg, Peter Calabresi, Solomon Snyder

Keywords(s): Chronic Inflammatory Diseases, CNS and Neurological Disorders, Disease Indication, Multiple Sclerosis, Multiple Sclerosis (MS), Neurodegeneration, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

1 2 3 4 5 6 7 8 9 10 ...